Sio Gene Therapies’ Exit From Oxford Biomedica Parkinson’s Collaboration Leaves Hole In Commercial Prospects

Firm Loses CEO

Sio Gene Therapies is returning its rights for a Parkinson’s disease program to Oxford Biomedica, leaving observers regretting the loss of a big market opportunity, while the US firms seeks a new CEO.    

Parkinson's disease, substantia nigra, Lewy bodies.
Parkinson's Disease Represented The Biggest Market Opportunity For The Firm, One Expert Said. • Source: Alamy

Sio Gene Therapies, Inc. plans to call it quits on a Parkinson’s disease-focused licensing deal with Oxford BioMedica plc as it instead prioritizes its internal pipeline, prompting some analysts to lower their commercial projections for the firm.

Sio has also been hit by the departure of CEO Pavan Cheruvu to pursue new opportunities; he is being replaced...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip